Cairns, Matthew http://orcid.org/0000-0003-1068-9713
Barry, Amadou
Zongo, Issaka
Sagara, Issaka
Yerbanga, Serge R.
Diarra, Modibo
Zoungrana, Charles
Issiaka, Djibrilla
Sienou, Abdoul Aziz
Tapily, Amadou
Sanogo, Koualy
Kaya, Mahamadou
Traore, Seydou
Diarra, Kalifa
Yalcouye, Hama
Sidibe, Youssoufa
Haro, Alassane
Thera, Ismaila
Snell, Paul
Grant, Jane
Tinto, Halidou
Milligan, Paul
Chandramohan, Daniel
Greenwood, Brian
Dicko, Alassane
Ouedraogo, Jean Bosco
Funding for this research was provided by:
Medical Research Council (MR/P006876/1)
PATH Malaria Vaccine Initiative (18269)
Wellcome Trust (220658/Z/20/Z)
Article History
Received: 26 April 2022
Accepted: 18 August 2022
First Online: 7 October 2022
Declarations
:
: The RTS,S-SMC trial protocol was approved by the ethics committees of the London School of Hygiene and Tropical Medicine, London (11872); the University of Science, Techniques and Technologies of Bamako, Mali (2016/134/CE/FMPOS); the Ministry of Health, Ouagadougou, Burkina Faso (2016-11-126); and by the national regulatory authorities of Burkina Faso and Mali. A Data Safety and Monitoring Board (DSMB) reviewed serious adverse events, approved the statistical analysis plan and archived the locked databases prior to unblinding. A steering committee gave scientific advice and monitored the progress of the trial. Written informed consent was obtained from the parents or guardians of all study children.
: Not applicable.
: The authors declare that they have no competing interests.